PACS in Massachusetts

QMENTA is a cloud-based medical imaging AI platform founded in 2013 that specializes in neuroimaging data management, processing, visualization, and analysis for clinical trials, research, and diagnostic support. The platform serves biopharmaceutical companies, CROs, medical device manufacturers, academic institutions, and diagnostic centers. QMENTA's integrated infrastructure includes Smart Uploader with HIPAA-compliant PHI de-identification, secure cloud PACS connectivity with automated workflows, over 50 AI-powered imaging biomarkers, Central Review capabilities for remote collaboration, and an Imaging Management System with EDC and query management tools. The company has processed 13M+ imaging scans for 1M+ study participants across 250+ connected sites and completed 1M+ AI imaging analyses. Solutions address neurological diseases, oncology, and rare disease diagnostics with demonstrated cost reductions (50%) and reading time improvements (75%).

PathAI is an AI-driven digital pathology company providing cloud-native software solutions for anatomic pathology laboratories, biopharma organizations, and clinical research. The company specializes in AI-powered histopathology analysis and digital pathology workflow management. PathAI's flagship platform, AISight®, is a cloud-native, open-architecture enterprise solution that integrates case management, image management, and AI-based diagnostic tools to enable multiple histopathology use cases. The platform serves as a central hub for digital pathology workflows across academic medical centers, reference laboratories, and health systems. AISight® Dx received FDA clearance for primary diagnosis in June 2025. PathAI also offers specialized AI-assisted tools including AIM-MASH (FDA-qualified for metabolic-associated fatty liver disease clinical trials) and AIM-HI UC/IBDExplore for standardized histopathology endpoints in clinical trials. The company operates a proprietary pathologist contributor network of board-certified pathologists to support algorithm training and validation, with millions of annotations contributed. Services include BioPharma solutions for drug and diagnostic development, central laboratory operations, and anatomic pathology lab solutions. Notable partnerships include expanded collaboration with Labcorp to deploy FDA-cleared digital pathology nationwide. The company combines pathology domain expertise with machine learning to advance precision medicine, biomarker discovery, and clinical trial standardization.

Cercare Medical A/S is a Denmark-based medical imaging software company specializing in advanced perfusion and metabolic imaging solutions for neurological and oncological applications. Founded in 2001 by Professor Kim Beuschau Mouridsen and PhD Mikkel Bo Hansen, the company develops automated, on-premise perfusion imaging software compatible with any MRI and CT scanner platform. Cercare Perfusion software generates unique biomarker maps including Capillary Transit-Time Heterogeneity (CTH), Oxygen Extraction Fraction (OEF), Cerebral Metabolic Rate of Oxygen (CMRO₂), relative Cerebral Blood Volume (rCBV), relative Cerebral Blood Flow (rCBF), and Mean Transit Time (MTT). Clinical applications include acute ischemic stroke assessment, brain tumor characterization and grading, neurodegenerative disease monitoring, and oncology applications. The Cercare Medical Neurosuite (CMN) integrates AI-enabled modules for automated detection and segmentation of hypoperfusion and ischemic core regions. The company's CBCT (cone-beam CT) perfusion capability provides real-time analysis in angiography suites, enabling direct-to-angio workflows and post-intervention assessment. Cercare operates globally with authorized distribution partners including Siemens, Terabox, AIDOC, VIZ, Sectra, and Microsoft, serving hospitals in multiple countries with over 1 million annual diagnoses supported. The software is vendor-agnostic, operates on-premise with no cloud dependency, and is designed for stroke, oncology, Alzheimer's disease, dementia, and neoplasia applications.

Butterfly Network manufactures and distributes the iQ3, a handheld, whole-body portable ultrasound probe for point-of-care ultrasound (POCUS) applications. The iQ3 integrates advanced AI-powered diagnostic capabilities, workflow management software, and a comprehensive education suite to enable clinicians across emergency medicine, primary care, obstetrics, and specialty practices to perform real-time ultrasound assessments at the bedside or point of care. The company serves individual practitioners, health systems, hospitals, and medical education institutions. Products include the iQ3 probe (FDA-cleared), with an established installed base of 145,000+ customers globally. The iQ3 represents an upgrade path from earlier Butterfly models (iQ, iQ+); trade-in programs are offered. Key software platform: Compass AI, a POCUS management module designed to centralize ultrasound workflows across health systems. Clinical applications include obstetric gestational age assessment, lung ultrasound (B-line detection), cardiac evaluation, and emergency diagnostic imaging. The company publishes clinical evidence demonstrating impact on patient outcomes, including reduced length of stay and improved charge capture in hospital deployments. Regulatory credentials include FDA 510(k) clearance. The platform emphasizes ease of use, portability, and seamless integration into clinical workflows for both resource-constrained and academic medical environments.

Revvity, Inc. is a comprehensive life science solutions provider serving academia, pharmaceutical, biotech, clinical laboratories, contract research organizations, and healthcare professionals globally. The company operates across the drug discovery-to-diagnostics continuum, delivering integrated workflows in translational multi-omics, biomarker identification, imaging, screening, detection, diagnosis, and informatics. Product portfolio includes high-content screening instruments (Opera Phenix, EnVision plate readers), optical imaging systems (IVIS), cell analysis instruments (Cellometer), sample preparation equipment (Omni Bead Ruptor Elite homogenizers), and laboratory automation (Fontus workstations, LabChip systems). Reagent brands encompass BioLegend antibodies and flow cytometry reagents, AlphaLISA and SureFire immunoassays, HTRF TR-FRET assays, Dharmacon RNAi and CRISPR tools, and custom oligonucleotide synthesis. Representative diagnostic and clinical service offerings include newborn screening (33M+ annual screens), immunodiagnostics via EUROIMMUN solutions (85M+ blood samples analyzed), infectious disease serology, TB testing (T-SPOT.TB, 20M+ tested since 2002), reproductive health solutions (maternal/prenatal testing, cell-free DNA analysis, preeclampsia management), and clinical genomics services (300M+ tests performed). Licensing portfolio covers gene expression, editing, and viral vector technologies including LentiBOOST and Pin-point base editing platforms. Revvity serves 94% of top 50 global pharma companies, maintains ~11,000 employees worldwide, and operates on-site manufacturing, viral vector engineering, preclinical oncology services, and clinical testing. Regulatory presence includes FDA and CE approvals across diagnostics and instruments. The company integrates acquisition-driven growth with organic R&D, supporting discovery through clinical deployment across life science workflows.

Picis Clinical Solutions develops cloud-based and on-premise surgical patient management and clinical information software for hospitals, ambulatory surgery centers (ASCs), and government healthcare facilities. The company specializes in perioperative software systems that integrate device data, enable seamless clinical documentation, and support workflow optimization across the surgical care continuum. Primary product suites include Perioperative Suite (perioperative documentation and patient flow), Clinical Information System Suite (cross-continuum care coordination), Experior ASC (combined clinical and practice management for surgical centers), and Government Suite (VA-integrated scheduling and workflow). Key specialized applications include Anesthesia Manager (device integration and historical data management), SmarTrack Next (perioperative patient tracking and communication), Orchestrator (surgical workflow management), PriorityQ (surgical scheduling optimization), RapidICU (crisis-mode ICU solutions), and Envision Analytics (healthcare business intelligence and revenue cycle analytics). Picis solutions are designed by clinicians for clinicians and emphasize interoperability, data synchronization across the perioperative suite, and decision support. The company serves hospitals, health systems, ASCs, and VA facilities internationally. Training and implementation support are available. Certifications and regulatory status not explicitly stated on homepage but inferred from healthcare software deployment context.

DeepHealth is a global leader in AI-powered health informatics and radiology solutions, headquartered in Somerville, Massachusetts and operating as a subsidiary of RadNet, Inc. Founded in 2015, the company develops cloud-native platforms that integrate diagnostic imaging tools with advanced artificial intelligence to enhance clinical workflows and patient outcomes. DeepHealth OS, the company's core cloud-native operating system, unifies enterprise data and provides AI-driven insights tailored for radiologists and care teams. The platform supports detection, assessment, and monitoring across multiple imaging modalities. Key clinical AI solutions include breast cancer screening (Breast Suite with ProFound Pro and Safeguard Review), lung cancer management, prostate health, and brain health diagnostics. DeepHealth's remote scanning capability (TechLive™) enables multimodality, vendor-agnostic imaging delivery. The company serves over 300 screening sites globally and processes more than 15 million annual exams across the U.S. and Europe. Recent strategic acquisitions of Gleamer, CIMAR UK, and Alpha RT assets have expanded DeepHealth's portfolio in clinical AI, image management, and remote staffing services.

Integrated Ophthalmic Systems, Inc. develops Continuum, a cloud-based ophthalmic image and data management platform designed for integration within electronic medical records (EMR) systems. The platform functions as a PACS (Picture Archiving and Communication System) specifically optimized for ophthalmology practices. Continuum processes and manages ophthalmic imaging across multiple modalities including optical coherence tomography (OCT), fundus photography, and other diagnostic imaging formats. The system features HL7/DICOM interoperability for seamless EMR integration, automatic patient demographic synchronization, and modality work list management to reduce manual data entry. Core capabilities include functional OCT visualization with B-scan review, thickness map analysis, segmentation layer viewing, and longitudinal comparison across multiple visits. Multi-modality image review allows side-by-side comparison of different imaging types across visit histories. The platform supports high availability, scalability, and redundancy with secure on-premises or Azure-based deployment options. LDAP integration enables Active Directory authentication for enterprise security. The company has processed more than 10 million clinical exams. The system integrates with third-party ophthalmic devices and platforms including Merge Eye Care PACS and Sonomed Escalon Axis equipment. FDA 510(k) clearance is indicated on the website, confirming regulatory approval for clinical use in the United States.

PaxeraHealth is a Boston-based enterprise medical imaging software company specializing in AI-driven imaging platforms and solutions. The company develops advanced Picture Archiving and Communication Systems (PACS), Radiology Information Systems (RIS), and vendor-neutral archive (VNA) platforms designed for healthcare providers globally. PaxeraHealth's core portfolio includes PaxeraUltimaAI—an AI-assisted enterprise imaging platform with native diagnostic algorithms to enhance workflow efficiency and reporting speed; ARK—a no-code imaging algorithm platform enabling users to develop multimodal AI algorithms without coding expertise; and VNAi—a data warehouse imaging platform providing secure, vendor-neutral control of imaging data with advanced lifecycle management. The company serves over 1,500 healthcare customers across 45 countries, managing 220+ million imaging studies annually. PaxeraHealth's solutions emphasize workflow automation, diagnostic accuracy improvement, clinical decision support, and seamless interoperability with existing EMR and PACS systems. The company employs approximately 106 people from 12 countries and maintains regional offices and a global distributor network to support healthcare systems of all sizes.

Foresight Imaging is an OEM manufacturer of high-performance video capture boards and PACS connectivity solutions for medical and defense imaging applications. ISO 13485 certified, the company has produced over 100,000 imaging boards in use at elite medical centers worldwide. Foresight Imaging specializes in high-accuracy video streamers and frame grabbers supporting multiple video signal types (HDMI, DVI, SDI, monochrome, RGB, analog, standard and non-standard formats) with sustained transfer rates up to 1.3 GB/second and advanced signal processing (±0.5 ns pixel jitter, 59 dB signal-to-noise ratio, 10-bit A/D conversion). The company's TIMS platform is a 510(k)-accredited analog-to-DICOM workstation solution combining image acquisition software with telemedicine capabilities for remote diagnostics. Applications include surgical recording, angiography, OCT, ultrasound imaging, and specialized medical visualization. Foresight provides comprehensive OEM support including software development kits (C libraries, DirectShow drivers, example programs in .NET, C++, Linux), technical engineering support during development, and automated configuration tools.

Ophthalmic Labs, Inc. is a supplier of ophthalmic imaging equipment and software solutions for eye care facilities. The company specializes in fundus cameras (new and refurbished), photo slit lamps, and digital imaging systems used for comprehensive eye examination and documentation. Core product lines include OVision™ imaging software (FDA 510(k) cleared), which enables digital photography and system upgrades; fundus camera sales and service; photo slit lamp systems; and legacy system migrations including IMAGEnet®, Merge/OIS Eye Station, OphthaVision, Canon®, and Visupac® platforms. The company offers both new equipment sales and refurbished units, digital conversion upgrades for obsolete legacy systems, and comprehensive service and refurbishment support. Ophthalmic Labs serves ophthalmology practices and eye clinics requiring diagnostic imaging and documentation capabilities. The company maintains parts inventory, provides maintenance services, and facilitates system migrations to modern Windows 10-based OVision™ platforms. FDA 510(k) clearance is prominently displayed, indicating regulatory compliance for imaging software and devices.